All Clarivate websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.
Optimism for the GoCAR-T program had perked somewhat after a mid-February update, but hopes were definitively dashed as Bellicum Pharmaceuticals Inc. made known March 15 its decision to quit the phase I/II study testing two prospects in heavily pretreated cancer. The Houston-based firm’s stock (NASDAQ:BLCM) closed at 43 cents, down 50%, as Wall Street reacted to news regarding the study, designed to test GoCAR-T cell prospects BPX-601 and BPX-603 when combined with the activating agent rimiducid, a lipid-permeable tacrolimus analogue.
Human trophoblastic cell surface antigen 2 (Trop2) is upregulated in cancers compared to normal tissues. Researchers from the University of Texas MD Anderson Cancer Center recently aimed to assess the clinical significance of Trop2 in small bowel adenocarcinoma (SBA).
Bladder small-cell carcinoma can be divided into different subtypes depending on the expression of neuroendocrine (NE) markers such as POU2F3, NEUROD1 and ASCL1. Single-cell RNA sequencing previously found a distinct subpopulation with high expression of 1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase gamma-2 (PLCG2) with pro-metastatic features and poor prognosis. The aim of a newer study was to evaluate the expression of PLCG2 in bladder NE tumors and correlate it with prognostic utility.
Suzhou Genhouse Bio Co. Ltd. has prepared and tested new histone deacetylase 6 (HDAC6) inhibitors reported to be useful for the treatment of cancer, asthma, Alzheimer’s diseases, diabetes, amyotrophic lateral sclerosis, multiple sclerosis, pulmonary fibrosis and psoriasis, among others.
A recent Nurix Therapeutics Inc. patent describes proteolysis targeting chimeras (PROTACs) comprising a cereblon (CRBN) E3 ubiquitin ligase-binding moiety coupled to interleukin-1 receptor-associated kinase 4 (IRAK-4) targeting moiety via a linker reported to be useful for the treatment of cancer, metabolic diseases and inflammatory disorders.
Eureka Therapeutics Inc. has entered into a license agreement with the National Cancer Institute (NCI) to develop and commercialize a novel antibody targeting mesothelin (MSLN) in combination with Eureka's proprietary Artemis T-cell receptor platform.
Researchers from the University of Pittsburgh Medical Center and affiliated organizations aimed to validate a novel marker of duodenal neuroendocrine tumors (DNETs), NKK6.2.
Limited data exist on checkpoint inhibition that targets the early activation phase of adaptive immunity. B-and T-lymphocyte attenuator (BTLA) blockade is known to enhance and broaden CD8+ T-cell responses to a target antigen.
A new experimental drug, QN-302, has shown high antiproliferative activity in pancreatic cancer cells and antitumor activity in experimental pancreatic cancer models.
RSS
